OmniaBio Inc., a subsidiary of CCRM, is the first project to be funded under the Invest Ontario Fund. Subject to reaching a definitive agreement, OmniaBio Inc. will be the recipient of a loan of up to $40 million from the Government of Ontario, funding that will kickstart the construction of a 250,000 square foot (23,225 square meter) contract development and manufacturing organization (CDMO) for cell and gene therapies (CGTs)—the largest facility of its kind in Canada. “We are grateful to th...